Is Valeant’s Big Offer for Allergan Big Enough?

Or is Valeant set to offer even more?

| More on:
The Motley Fool

On April 22, 2014, Valeant Pharmaceuticals (TSX: VRX)(NYSE: VRX) made an unsolicited offer of around $46 billion to the shareholders of Allergan (NYSE: AGN), a top-tier pharmaceutical company. The cash and share offer, which amounted to around $154 per Allergan share, represented a substantial premium compared to the $115-$125 price prevailing in the weeks before the offer was made.

After the Allergan board’s rejection of the initial offer, the Valeant board improved the offer further on two occasions. On May 28, 2014, the cash component of the offer was increased to $58.30 per share from $48.30 per share, and again to $73 per share two days later. The 0.83 share exchange ratio remained unchanged but Valeant also included a contingent value right linked to future sales of a drug that is still under development.

Based on the current share price of Valeant, the offer is worth around $183 per Allergan share, excluding the speculative component of the contingent value right. The offer values Allergan at a 2014 EV/EBITDA ratio of 21 times; this is considerably higher than the valuation of a representative peer group, which trades on an estimated multiple of 12 times. Based on Valeant’s calculation of $2.7 billion in savings through a business combination, the offer multiple could drop to an estimated 14.5 times, which would still represent a considerable premium to the peer group valuation.

Will Valeant increase the offer a third time?

The offer on the table is, in my view, already a full price for Allergan. In addition, Valeant has limited options to further increase the cash component of the offer given its already stretched balance sheet and limitations on the issue of additional shares. Apart from marginal tweaking, it is therefore unlikely that the offer will be further materially improved.

What will Allergan’s shareholders do?

Apart from the two bidding parties (Valeant and Pershing Square, which combined hold 9.7% of Allergan’s shares), the other shareholders are mainly investment funds. Although this battle may continue for much longer with interesting twists and turns, one could imagine that these shareholders would look to optimize the windfall profit brought about by the Valeant offer.

Given the rich offer already on the table, the considerable execution risks to Allergan’s shareholders, and perceptions of an inflated Valeant share price and unsustainable business model, current Allergan shareholders may be tempted to sell their stock in the market to lock in the considerable gains they have already experienced.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Deon Vernooy does not hold a position in any company mentioned above.

More on Investing

stock research, analyze data

Should You Buy Telus Stock for its 5.9% Dividend Yield?

Telus (TSX:T) stock has a great dividend yield and newfound momentum since bottoming in October.

Read more »

The sun sets behind a high voltage telecom tower.
Dividend Stocks

My 2 Favourite TSX Utility Stocks for December 2023

While typically seen as boring, utility stocks can be excellent for safe dividend income. Here are two of my favourite…

Read more »

Dividend Stocks

How to Make $1,000/Year With Enbridge Stock

Enbridge’s unwavering commitment to maintaining and increasing its dividend makes it a top passive-income stock.

Read more »

A bull outlined against a field
Tech Stocks

3 Undervalued Canadian Stocks Set for a Bull Run

Investing in cheap and undervalued TSX stocks such as Cargojet and Real Matters can help you beat the broader indices…

Read more »

tsx today
Energy Stocks

TSX Today: What to Watch for in Stocks on Thursday, December 7

An early morning recovery in commodity prices could lift the main TSX index at the open today.

Read more »

Aircraft wing plane

Prediction: Air Canada Stock Will Sit on the Runway for a While

Will Air Canada stock be able to continue to ride post-pandemic tailwinds, or is this stock pricing in an upcoming…

Read more »

Businessman holding AI cloud
Tech Stocks

Artificial Intelligence, Real Returns: Profiting From the AI Revolution

Tech companies like Shopify Inc (TSX:SHOP) are profiting from the AI revolution.

Read more »

Paper airplanes flying on blue sky with form of growing graph

Are Airline Stocks a Good Buy in December 2023?

Airline stocks are cyclical. So, interested investors should aim to buy low and sell high to target price appreciation.

Read more »